Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer

Nature Clinical Practice Urology volume 2, pages 136–142 (2005)Cite this article

Abstract

This review summarizes the case for active surveillance of 'good-risk' prostate cancer, with selective delayed intervention for rapid biochemical progression, assessed by rising prostate-specific antigen (PSA) levels or grade progression. The results of a large phase II trial using this approach are also reviewed. A prospective phase II study of active surveillance with selective delayed intervention was initiated in 1995. Patients were managed initially with surveillance; those who had a PSA doubling time (PSADT) of ≤2 years, or grade progression on repeat biopsy, were offered radical intervention. The remaining patients were closely monitored. The cohort now consists of 299 patients with good-risk—or, in men over 70 years of age, intermediate-risk—prostate cancer. The median PSADT was 7 years, 42% had a PSADT >10 years. The majority of patients remain on surveillance. At 8 years, overall actuarial survival was 85%, and disease-specific survival was 99%.To date, this study has shown that most men with 'good-risk' prostate cancer will die of unrelated causes. The approach of active surveillance with selective delayed intervention based on PSADT represents a practical compromise between radical therapy for all patients, which results in overtreatment for patients with indolent disease, and watchful waiting with palliative therapy only, which results in undertreatment for those with aggressive disease. The results at 8 years were favorable. Longer follow-up will be required if the study is to confirm the safety of this approach in men with a long life expectancy (>15 years).

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sakr WA et al. (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379–385

    Article  CAS  Google Scholar 

  2. Stamey TA et al. (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (Suppl 3): S933–S938

    Article  Google Scholar 

  3. Boring CC et al. (1993) Cancer statistics, 1993. CA Cancer J Clin 43: 7–26

    Article  CAS  Google Scholar 

  4. Jemal A et al. (2004) Cancer Statistics, 2004. CA Cancer J Clin 54: 8–29

    Article  Google Scholar 

  5. Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224

    Article  CAS  Google Scholar 

  6. McGregor M et al. (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159: 1368–1372

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Etzioni R et al. (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94: 981–990

    Article  Google Scholar 

  8. Singh H et al. (2004) Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 171: 1089–1092

    Article  Google Scholar 

  9. Presti JC Jr (2003) Prostate biopsy: how many cores are enough? Urol Oncol 21: 135–140

    Article  Google Scholar 

  10. Sakr WA et al. (1996) Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 30: 138–144

    Article  CAS  Google Scholar 

  11. Pound C et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597

    Article  CAS  Google Scholar 

  12. Cooperberg MR et al. (2003) Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170 (Suppl): S21–S25

    PubMed  Google Scholar 

  13. Albertsen P et al. (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975–980

    Article  CAS  Google Scholar 

  14. Chodak G (1994) The role of watchful waiting in the management of localized prostate cancer. J Urol 152: 1766–1768

    Article  CAS  Google Scholar 

  15. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125–135

    Article  CAS  Google Scholar 

  16. Aus G et al. (1995) Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154: 460–465

    Article  CAS  Google Scholar 

  17. Johansson JE et al. (2004) Natural history of early, localized prostate cancer. JAMA 291: 2713–2719

    Article  CAS  Google Scholar 

  18. Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5: 101–106

    Article  Google Scholar 

  19. Parker C (2003) Active surveillance: an individualized approach to early prostate cancer. BJU Int 92: 2–3

    Article  CAS  Google Scholar 

  20. Choo R et al. (2002) Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167: 1664–1669

    Article  Google Scholar 

  21. Choo R et al. (2001) PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50: 615–620

    Article  CAS  Google Scholar 

  22. Epstein JI et al. (2001) Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166: 1688–1691

    Article  CAS  Google Scholar 

  23. Epstein JI et al. (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368–374

    Article  CAS  Google Scholar 

  24. Epstein JI et al. (1993) Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582–3593

    Article  CAS  Google Scholar 

  25. Epstein JI et al. (1993) Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 149: 1478–1481

    Article  CAS  Google Scholar 

  26. Epstein JI et al. (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160: 2407–2411

    Article  CAS  Google Scholar 

  27. Goto Y et al. (1996) Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156: 1059–1063

    Article  CAS  Google Scholar 

  28. Kattan MW et al. (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170: 1792–1797

    Article  Google Scholar 

  29. Augustin H et al. (2003) Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 43: 455–460

    Article  Google Scholar 

  30. Noguchi M et al. (2001) Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 166: 104–109

    Article  CAS  Google Scholar 

  31. Stamey TA et al. (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172: 1297–1301

    Article  Google Scholar 

  32. Schmid HP et al. (1993) Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031–2040

    Article  CAS  Google Scholar 

  33. Hanks GE et al. (1996) Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34: 549–553

    Article  CAS  Google Scholar 

  34. D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376–1383

    Article  Google Scholar 

  35. McLaren DB et al. (1998) Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 82: 342–348

    Article  CAS  Google Scholar 

  36. Egawa S et al. (2000) Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3: 269–274

    Article  CAS  Google Scholar 

  37. Berges RR et al. (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1: 473–480

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Egawa S et al. (1999) Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. Cancer 86: 463–469

    Article  CAS  Google Scholar 

  39. Bangma CH (1995) Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate. J Urol 154: 1403–1406

    Article  CAS  Google Scholar 

  40. Gerber GS et al. (1998) Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol 159: 1243–1246

    Article  CAS  Google Scholar 

  41. Vollmer RT et al. (2002) The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer 94: 1692–1698

    Article  Google Scholar 

  42. Do V et al. (2002) The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int 89: 703–709

    Article  CAS  Google Scholar 

  43. Steineck G et al. (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347: 790–796

    Article  Google Scholar 

  44. Hanash K et al. (1972) Carcinoma of the prostate: a 15-year followup. J Urol 107: 450–453

    Article  CAS  Google Scholar 

  45. Lerner S et al. (1991) The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146: 1040–1045

    Article  CAS  Google Scholar 

  46. Schmid HP et al. (2001) Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. A review. Eur Urol 40: 488–494

    Article  CAS  Google Scholar 

  47. Handley R et al. (1988) Deferred treatment for prostate cancer. Br J Urol 62: 249–253

    Article  CAS  Google Scholar 

  48. Waaler G and Stenwig AE (1993) Prognosis of localised prostatic cancer managed by “watch and wait” policy. Br J Urol 72: 214–219

    Article  CAS  Google Scholar 

  49. Whitmore W et al. (1991) Expectant management of localized prostatic cancer. Cancer 67: 1091–1096

    Article  Google Scholar 

  50. George NJ (1988) Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1: 494–497

    Article  CAS  Google Scholar 

  51. Holmberg L et al. (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347: 781–789

    Article  Google Scholar 

  52. Foley J and Thompson I (2000) Natural history of localized adenocarcinoma of prostate. In Advanced therapy of prostate disease, 87–91 (Eds Resnick M and Thompson I) London: BC Decker, Inc

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Toronto,

    Laurence Klotz

  2. Division of Urology, Sunnybrook & Women's College Health Sciences Centre, Toronto, Canada

    Laurence Klotz

Authors
  1. Laurence Klotz
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Laurence Klotz.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

PSA DOUBLING TIME (PSADT)

The time taken for the detected PSA level to double. This test is used as an indicator of the rate of disease progression in patients with prostate cancer

PERCENTAGE FREE PSA (%fPSA)

The percentage of PSA in the blood that is found unbound to proteins. Prostate cancer is associated with a lower percent free serum PSA than benign prostate tissue

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klotz, L. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Rev Urol 2, 136–142 (2005). https://doi.org/10.1038/ncpuro0124

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpuro0124

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing